450 related articles for article (PubMed ID: 34071582)
1. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
Sivakumar D; Stein M
Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
[TBL] [Abstract][Full Text] [Related]
2. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
Awoonor-Williams E; Abu-Saleh AAA
Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
[TBL] [Abstract][Full Text] [Related]
3. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
Rahul S; Sarkar A
J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
[TBL] [Abstract][Full Text] [Related]
4. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
Freitas BT; Durie IA; Murray J; Longo JE; Miller HC; Crich D; Hogan RJ; Tripp RA; Pegan SD
ACS Infect Dis; 2020 Aug; 6(8):2099-2109. PubMed ID: 32428392
[TBL] [Abstract][Full Text] [Related]
5. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design.
Rut W; Lv Z; Zmudzinski M; Patchett S; Nayak D; Snipas SJ; El Oualid F; Huang TT; Bekes M; Drag M; Olsen SK
Sci Adv; 2020 Oct; 6(42):. PubMed ID: 33067239
[TBL] [Abstract][Full Text] [Related]
6. A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2.
Singh E; Jha RK; Khan RJ; Kumar A; Jain M; Muthukumaran J; Singh AK
Comput Biol Chem; 2022 Aug; 99():107721. PubMed ID: 35835027
[TBL] [Abstract][Full Text] [Related]
7. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
[TBL] [Abstract][Full Text] [Related]
8. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2.
Sanders BC; Pokhrel S; Labbe AD; Mathews II; Cooper CJ; Davidson RB; Phillips G; Weiss KL; Zhang Q; O'Neill H; Kaur M; Schmidt JG; Reichard W; Surendranathan S; Parvathareddy J; Phillips L; Rainville C; Sterner DE; Kumaran D; Andi B; Babnigg G; Moriarty NW; Adams PD; Joachimiak A; Hurst BL; Kumar S; Butt TR; Jonsson CB; Ferrins L; Wakatsuki S; Galanie S; Head MS; Parks JM
Nat Commun; 2023 Mar; 14(1):1733. PubMed ID: 36977673
[TBL] [Abstract][Full Text] [Related]
9. Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease.
Hognon C; Marazzi M; García-Iriepa C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628665
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity.
Weng YL; Naik SR; Dingelstad N; Lugo MR; Kalyaanamoorthy S; Ganesan A
Sci Rep; 2021 Apr; 11(1):7429. PubMed ID: 33795718
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease.
Liu W; Wang J; Wang S; Yue K; Hu Y; Liu X; Wang L; Wan S; Xu X
Bioorg Chem; 2023 Nov; 140():106830. PubMed ID: 37683544
[TBL] [Abstract][Full Text] [Related]
12. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.
Bosken YK; Cholko T; Lou YC; Wu KP; Chang CA
Front Mol Biosci; 2020; 7():174. PubMed ID: 32850963
[TBL] [Abstract][Full Text] [Related]
13. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
14. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
15. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
Amin SA; Ghosh K; Gayen S; Jha T
J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
17. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
